DDL, a provider of package, product, and material testing services, announced on Monday the opening of a new Good Manufacturing Practice (GMP) laboratory for drug-device combination product testing.
This expansion enhances DDL's capacity to support the pharmaceutical, biotech and combination product industries with rigorous, regulatory-compliant testing solutions.
The new FDA-registered 10,600 sq ft GMP lab is located near DDL's headquarters in Eden Prairie, Minnesota. The lab will offer ICH stability testing, functional and mechanical performance testing (ISO 11040 & ISO 11608) and simulated distribution testing to meet the growing demand for high-quality GMP testing for devices such as auto injectors, pre-filled syringes, inhalers and other combination products.
DDL said that its new facility will provide comprehensive testing solutions in accordance with FDA, ISO and other global regulatory standards.
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Realheart secures European patent for artificial heart technology
Median Technologies secures FDA clearance for AI lung cancer screening software
Eli Lilly to invest over USD3.5bn in new Pennsylvania plant
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Zylox-Tonbridge agrees staged acquisition of Germany's Optimed
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Boston Scientific to acquire Valencia Technologies to expand overactive bladder portfolio
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics